Entry |
|
Name |
Rilpivirine hydrochloride, tenofovir disoproxil fumarate and emtricitabine; Complera (TN); Eviplera (TN) |
Product |
|
Component |
Rilpivirine hydrochloride [DR: D09958], Tenofovir disoproxil fumarate [DR: D01982], Emtricitabine [DR: D01199]
|
Remark |
Therapeutic category: | 6250 |
|
Efficacy |
Antiviral |
Disease |
|
Comment |
Rilpivirine is primarily metabolized by CYP3A.
|
Target |
RNA-directed DNA polymerase |
Metabolism |
|
Interaction |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AR Antivirals for treatment of HIV infections, combinations
J05AR08 Emtricitabine, tenofovir disoproxil and rilpivirine
D10571 Rilpivirine hydrochloride, tenofovir disoproxil fumarate and emtricitabine <US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Combinations
Emtricitabine/ Rilpivirine / Tenofovir Disoproxil Fumarate
D10571 Rilpivirine hydrochloride, tenofovir disoproxil fumarate and emtricitabine
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D10571 Rilpivirine hydrochloride, tenofovir disoproxil fumarate and emtricitabine
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10571
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10571
|
Other DBs |
|